Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 3/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267758 | 0.86 | MAPK1 (0.44) | MEN1POLBMAPK1KMT2AAHR | |
| SCHEMBL13930945 | 0.79 | MEN1 (0.44) | MEN1POLBMAPK1KMT2AAHR | |
| SCHEMBL84519 | 0.78 | AHR (0.50) | MEN1POLBMAPK1KMT2AAHR | |
| SCHEMBL6089775 | 0.75 | TYR (0.47) | MEN1POLBMAPK1KMT2AAHR | |
| SCHEMBL19513331 | 0.74 | METAP2 (0.57) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL26823824 | 0.73 | BRD4 (0.39) | — | |
| SCHEMBL23815001 | 0.72 | AHR (0.44) | MAPK1AHRCYP2A6MAOACHRNB4 | |
| SCHEMBL21110227 | 0.72 | MEN1 (0.44) | MEN1POLBMAPK1KMT2AAHR | |
| SCHEMBL19646434 | 0.72 | NOTUM (0.35) | MAPK1ESR1CNR2CNR1 | |
| SCHEMBL19006218 | 0.72 | MEN1 (0.39) | MEN1POLBMAPK1KMT2AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | CPS1, CPSF1, CPSF7 | MEN1 3585/4885POLB 1807/4885MAPK1 4066/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MEN1 3174/4885POLB 1191/4885MAPK1 234/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MEN1 3174/4885POLB 1191/4885MAPK1 234/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MEN1 606/4885POLB 3726/4885MAPK1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.